King's College London
His scientific interests lie mostly in Chimeric antigen receptor, Immunotherapy, Immunology, Antigen and Cell biology. The Chimeric antigen receptor study combines topics in areas such as CD28, ErbB, Adoptive cell transfer and Interleukin 4. His work on Cancer immunotherapy as part of general Immunotherapy study is frequently linked to Viral vector, therefore connecting diverse disciplines of science.
While the research belongs to areas of Immunology, John Maher spends his time largely on the problem of Cell, intersecting his research to questions surrounding Malignant disease. John Maher focuses mostly in the field of Cell biology, narrowing it down to topics relating to Tumor microenvironment and, in certain cases, Signal transducing adaptor protein, Virology, Calcium flux and Mucin. His ErbB Receptors study incorporates themes from Carcinogenesis and Cancer research.
John Maher mostly deals with Chimeric antigen receptor, Cancer research, Immunotherapy, Immunology and Cancer. The concepts of his Chimeric antigen receptor study are interwoven with issues in CD28, Adoptive cell transfer, Cancer immunotherapy and ErbB. His work deals with themes such as Molecular biology, Integrin and Cell biology, which intersect with CD28.
His Cancer research research incorporates elements of Receptor, Car t cells, Mesothelioma and ErbB Receptors. His work carried out in the field of Immunotherapy brings together such families of science as Cell, Tumor microenvironment, T cell, Cytokine receptor and In vivo. His Antigen study integrates concerns from other disciplines, such as Ex vivo and T-cell receptor.
The scientist’s investigation covers issues in Cancer research, Chimeric antigen receptor, Car t cells, Immunotherapy and T cell. John Maher has researched Cancer research in several fields, including Homing, MUC1, Cytotoxicity, MTT assay and External beam radiotherapy. In the field of Chimeric antigen receptor, his study on CAR T-cell therapy overlaps with subjects such as Synergistic combination.
John Maher has included themes like Hypoxia, Cytokine release syndrome, Clinical trial and ErbB Receptors in his Car t cells study. His research in Immunotherapy intersects with topics in Cancer cell, Head and neck cancer, Chemotherapy and ErbB. His research in T cell is mostly focused on CD28.
His primary areas of study are Chimeric antigen receptor, Cancer research, Immunotherapy, Homing and T cell. His study in Car t cells and CAR T-cell therapy falls within the category of Chimeric antigen receptor. His Cancer research research integrates issues from In vivo and Cytotoxicity.
His studies deal with areas such as MUC1 and Monoclonal antibody as well as Immunotherapy. His MUC1 research is multidisciplinary, incorporating perspectives in CD28, Granzyme B and Triple-negative breast cancer. His Homing research incorporates themes from Cancer stem cell and Angiogenesis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher;Renier J Brentjens;Gertrude Gunset;Isabelle Rivière.
Nature Biotechnology (2002)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie;May C. I. van Schalkwyk;Steve Hobbs;David M. Davies.
Journal of Clinical Immunology (2012)
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.
Scott Wilkie;Gianfranco Picco;Julie Foster;David M. Davies.
Journal of Immunology (2008)
Nucleic acids encoding chimeric T cell receptors
Michel Sadelain;Renier Brentjens;John Maher.
Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.
Dominic A. Boardman;Christina Philippeos;Gilbert O. Fruhwirth;Mohammad A. A. Ibrahim.
American Journal of Transplantation (2017)
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
Scott Wilkie;Sophie E. Burbridge;Laura Chiapero-Stanke;Ana C.P. Pereira.
Journal of Biological Chemistry (2010)
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9
Richard Beatson;Virginia Tajadura-Ortega;Daniela Yordanova Achkova;Gianfranco Picco.
Nature Immunology (2016)
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Pei Yun Teo;Chuan Yang;Lynsey M. Whilding;Lynsey M. Whilding;Ana C. Parente-Pereira.
Advanced Healthcare Materials (2015)
Targeting cytotoxic T lymphocytes for cancer immunotherapy
John Maher;E T Davies.
British Journal of Cancer (2004)
Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice.
Ana Caterina Parente-Pereira;Jerome Burnet;David Ellison;Julie Foster.
Journal of Clinical Immunology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: